Tourette Syndrome | Unmet Need | US/FR/DE/UK | 2020
Tourette syndrome is a neurological disorder characterized by repetitive, uncontrollable movements and/or unwanted vocal sounds (tics) and typically begins in childhood. Tics range from mild to severe and can therefore significantly affect communication, daily functioning, and quality of life. Aripiprazole, pimozide, and haloperidol are the only therapies with formal approval in either the United States or Europe for Tourette syndrome, but alpha-2 agonists and dopamine-depleting agents are also used off-label. Because pharmacological treatments are usually only partially effective for controlling tics and carry unwanted side effects including somnolence, weight gain, and drug-induced movement disorders, substantial unmet need persists for more effective treatment options.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for Tourette syndrome?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- What are the prevailing areas of unmet need and opportunity in Tourette syndrome?
- What are the commercial opportunities for emerging Tourette syndrome therapies, such as Teva’s deutetrabenazine, Therapix Biosciences’ dronabinol / palmitoylethanolamide, Emalex Biosciences’ ecopipam, and Abide / Lundbeck’s ABX 1431?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new Tourette syndrome drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European neurologists fielded in January 2020
Key companies: Janssen, Lundbeck, Otsuka Pharmaceutical, Teva, Emalex Biosciences
Key drugs: Aripiprazole, clonidine, guanfacine, pimozide, risperidone, tetrabenazine, tiapride
